has shown that in murine models of KRAS G12D/p53- lung cancer, the combination of trametinib with anti-PD-1 or anti-PD-L1 immune-checkpoint inhibitors has synergistic anti-tumor effect; this might be explained by an immunomodulatory effect of trametinib that, according to the authors, might be determined by the depletion of PMN-MDSC from the tumor microenvironment (91). Here, KRAS is linked to lung carcinoma.